Steven Rubin, MD
Gastroenterology · Merrick, NYNPI 1568435931
Payments from drug & device makers
Across 1,166 payments — averaging $189.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$111K
- Ardelyx, Inc.$22K
- Nestle Healthcare Nutrition Inc.$20K
- Vivus LLC$18K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$15K
- Phathom Pharmaceuticals, Inc.$10K
- plus $25K from 25 others
Across 1 payment — averaging $1400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$1K
What the payments were for
- Consulting fees$23,78311%
- Speaking & faculty fees$154,35370%
- Travel & lodging$16,8808%
- Food & beverage$25,52512%
- Education$280%
- Other$2600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 412 | $110,817 |
| Ardelyx, Inc. | 77 | $21,528 |
| Nestle Healthcare Nutrition Inc. | 95 | $20,121 |
| Vivus LLC | 36 | $17,956 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 147 | $14,842 |
| Phathom Pharmaceuticals, Inc. | 39 | $10,260 |
| Aimmune Therapeutics, Inc. | 38 | $8,929 |
| Takeda Pharmaceuticals U.S.A., Inc. | 72 | $8,780 |
| QOL Medical, LLC | 92 | $3,717 |
| Ironwood Pharmaceuticals, Inc | 43 | $784 |
| Pfizer | 26 | $696 |
| Bristol Myers Squibb | 30 | $515 |
| Redhill Biopharma Inc. | 14 | $297 |
| Olympus America Inc. | 3 | $294 |
| Johnson & Johnson | 11 | $263 |
| E.r. Squibb & Sons, L.L.C. | 2 | $249 |
| Intuity Medical Inc | 1 | $125 |
| Boehringer Ingelheim | 1 | $121 |
| Novo Nordisk | 4 | $80 |
| Intercept Pharmaceuticals, Inc. | 3 | $63 |
| Sanofi | 3 | $61 |
| Ferring Pharmaceuticals Inc. | 3 | $61 |
| Ipsen Biopharmaceuticals, Inc | 3 | $58 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| Evoke Pharma, Inc. | 1 | $23 |
| Micro-tech Endoscopy USA, Inc. | 2 | $23 |
| Alfasigma USA, Inc. | 1 | $20 |
| W. L. Gore & Associates, Inc. | 1 | $19 |
| UCB, Inc. | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$220,827 in reported general payments places this provider in the 95th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 116 | $657,740 |
| ZenpepLipase/Protease/Amylase | 56 | $441,955 |
| SucraidSacrosidase | 11 | $151,607 |
| PancreazeLipase/Protease/Amylase | 23 | $73,122 |
| LinzessLinaclotide | 30 | $45,096 |
| Mesalamine | 34 | $35,880 |
| VoqueznaVonoprazan Fumarate | 33 | $29,331 |
| Mesalamine ErMesalamine | 12 | $8,923 |
| Lubiprostone | 16 | $7,282 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 78 | $4,872 |
| Omeprazole | 322 | $3,646 |
| Mercaptopurine | 16 | $3,024 |
| Pantoprazole Sodium | 59 | $1,133 |
| Metronidazole | 16 | $653 |
| Lactulose | 11 | $512 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess | $110,817 | $702,836146 claims |
| Aimmune Therapeutics, Inc.Zenpep | $8,929 | $441,95556 claims |
| QOL Medical, LLCSucraid | $3,717 | $151,60711 claims |
| Vivus LLCPancreaze | $17,956 | $73,12223 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $10,260 | $29,33133 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,682 gastroenterology providers in New York.
Other gastroenterology in Merrick
- Michael GerdisYonkers$11.9M
- David HudesmanNew York$3.6M
- Ellen ScherlNew York$2.9M
- Igor GrosmanBrooklyn$2.8M
- Bruce SandsNew York$2.8M
- Arun SwaminathNew York$2.7M
- Sonal KumarNew York$2.3M
- David Carr LockeNew York$2.1M
- Arthur KornbluthNew York$1.9M
- Maya SrivastavaWilliamsville$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.